GR3033482T3 - Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions. - Google Patents

Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions.

Info

Publication number
GR3033482T3
GR3033482T3 GR20000401179T GR20000401179T GR3033482T3 GR 3033482 T3 GR3033482 T3 GR 3033482T3 GR 20000401179 T GR20000401179 T GR 20000401179T GR 20000401179 T GR20000401179 T GR 20000401179T GR 3033482 T3 GR3033482 T3 GR 3033482T3
Authority
GR
Greece
Prior art keywords
endonexin
hepatitis
polypeptides
diagnostic
derived
Prior art date
Application number
GR20000401179T
Other languages
English (en)
Inventor
Sing-Hiem Yap
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of GR3033482T3 publication Critical patent/GR3033482T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR20000401179T 1992-07-08 2000-05-24 Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions. GR3033482T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP92401971 1992-07-08
PCT/EP1993/001745 WO1994001554A1 (en) 1992-07-08 1993-07-06 Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions
EP93915810A EP0672136B1 (en) 1992-07-08 1993-07-06 Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
GR3033482T3 true GR3033482T3 (en) 2000-09-29

Family

ID=8211682

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000401179T GR3033482T3 (en) 1992-07-08 2000-05-24 Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions.

Country Status (12)

Country Link
EP (2) EP0968648A1 (el)
JP (2) JPH07509776A (el)
AT (1) ATE190351T1 (el)
AU (1) AU676483B2 (el)
CA (1) CA2139735A1 (el)
DE (1) DE69328035T2 (el)
DK (1) DK0672136T3 (el)
ES (1) ES2146231T3 (el)
GR (1) GR3033482T3 (el)
PT (1) PT672136E (el)
SG (1) SG46493A1 (el)
WO (1) WO1994001554A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0741144B1 (en) * 1994-11-11 2002-07-24 Noboru Kaneko Antiannexin-v monoclonal antibody, process for producing the same, and use therof
JP2001508054A (ja) * 1996-12-30 2001-06-19 イノジェネティックス・ナムローゼ・フェンノートシャップ ＨＢｓＡｇ由来アネキシンＶ結合ポリペプチドおよびその使用
WO1999024054A1 (en) * 1997-11-06 1999-05-20 Innogenetics N.V. Host derived proteins binding hcv: medical, diagnostic and purification use
US6344362B1 (en) 1998-03-12 2002-02-05 Ministero Dell Universita'e Della Ricerca Scientifica E Tecnologica (M.U.R.S.T. ) Use of a recombinant protein as receptor of a hepatitis virus
IT1299581B1 (it) * 1998-03-12 2000-03-16 Ministero Dell Uni Della Ricer Uso di una proteina ricombinante come recettore di un virus dell'epatite
CA2335102A1 (en) * 1998-09-01 2000-03-09 Innogenetics N.V. Benzodiazepines and benzothiazepines derivatives and hbsag peptides binding to annexins, their compositions and use
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
EP1839670A3 (en) 2001-02-21 2009-11-11 Alavita Pharmaceuticals, Inc. Modified Annexin Proteins and their use against thrombosis
US20060057591A1 (en) * 2004-09-15 2006-03-16 Canadian Blood Services Method for preventing viral infection
JP2008537483A (ja) 2005-03-15 2008-09-18 イノジェネティックス・ナムローゼ・フェンノートシャップ ヌクレオシドアナログに対する感受性を低減したｂ型肝炎ウイルス変種およびその使用
US8383879B2 (en) * 2009-12-04 2013-02-26 Academia Sinica Non-human animal disease mode for hepatitis B virus-associated disease
EP2917230B1 (en) * 2012-11-12 2018-07-18 Ruprecht-Karls-Universität Heidelberg Development of hbv- and/or hdv-susceptible cells, cell lines and non-human animals

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI861417A0 (fi) * 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
PT87083B (pt) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
EP0288198A3 (en) * 1987-04-20 1989-03-29 Takeda Chemical Industries, Ltd. Production of peptide
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
DE3737239A1 (de) * 1987-11-03 1989-10-12 Behringwerke Ag Gentechnische herstellung von anticoagulatorischem protein pp4
AU3231189A (en) * 1988-03-31 1989-10-05 Rorer International (Overseas) Inc. Recombinant endonexin ii
FR2637184A1 (fr) * 1988-10-05 1990-04-06 Inst Nat Sante Rech Med Anticorps monoclonal reconnaissant une region pre-s1 de la grande proteine d'enveloppe du virus de l'hepatite b et ses applications, notamment pour le diagnostic in vitro et le traitement de l'hepatite b
EP0389983A3 (en) * 1989-03-31 1991-01-16 Abbott Laboratories Monoclonal antibodies to pres2 and pres1 polypeptides of the hepatitis b viral envelope
DE4012341A1 (de) * 1990-04-18 1991-10-24 Behringwerke Ag Monoklonale antikoerper gegen pp4, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
EP0672136B1 (en) 2000-03-08
EP0672136A1 (en) 1995-09-20
JP2003189759A (ja) 2003-07-08
DE69328035T2 (de) 2000-11-02
EP0968648A1 (en) 2000-01-05
ATE190351T1 (de) 2000-03-15
PT672136E (pt) 2000-08-31
CA2139735A1 (en) 1994-01-20
WO1994001554A1 (en) 1994-01-20
AU4564693A (en) 1994-01-31
ES2146231T3 (es) 2000-08-01
DE69328035D1 (de) 2000-04-13
DK0672136T3 (da) 2000-08-21
AU676483B2 (en) 1997-03-13
JPH07509776A (ja) 1995-10-26
SG46493A1 (en) 1998-02-20

Similar Documents

Publication Publication Date Title
GR3033482T3 (en) Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions.
DK0591914T4 (da) Retrovirus fra HIV-gruppen og dets anvendelse
PT725824E (pt) Epitopos de celulas t humanas imunodominantes do virus da hepatite c
LU90911I2 (fr) Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare
FI910286A0 (fi) Analoger av humant insulin och preparat innehaollande dessa.
ATE72406T1 (de) Vorrichtung zur applikation von implantaten.
ATE140969T1 (de) Il-3 mit zusätzlichen cysteinresten und chemische modifikationen davon
ATE179429T1 (de) Cytokine dämpfende substanzen
CA2189250A1 (en) Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
CA2215203A1 (en) Vaccines for plague
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
ZA923321B (en) Recombinant avipox virus,the culture of cells infected by this virus and vaccines for poultry derived from this virus
IT8619055A0 (it) Composizioni farmaceutiche comprendenti peptidi del gruppo colecistochinina-cerulina per il trattamento terapeutico degli statidi shock e dell'insufficienza respiratoria e cardiocircolatoria.
HU9300187D0 (en) Applications of recombinant dna of synoythioma virus proteines, vaccines, antibodies and transformed cells of cattle's breathing organs
EP0712926A3 (el)
ATE67783T1 (de) Homogene rekombinante immun-interferon-fragmente und diese enthaltende pharmazeutische zusammensetzungen.
DE68912478D1 (de) Rekombinantes Marek-Krankheitsvirus, Verfahren zu seiner Herstellung, und Vakzine.
ZA895419B (en) Non-glycosylated,recombinant human il2 in reduced form,process for obtaining it and its use as a medicament
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.
ATE133074T1 (de) Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen- herausforderungen
Centers for Disease Control (CDC Anonymous survey for simian immunodeficiency virus (SIV) seropositivity in SIV-laboratory researchers--United States, 1992
Centers for Disease Control and Prevention (CDC Availability of new rabies vaccine for human use
JPS6429A (en) Antiviral agent
FR2655855B1 (fr) Protection genetique d'animaux contre l'infection par le virus leucemogene bovin, et provirus et virus recombinant derive de ce virus.

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees